Jerry St Peter to spearhead NicOx expansion in US
Aims to build an international ophthalmology company
St Peter has extensive knowledge of the ophthalmology market in the US. Most recently, he developed the commercial unit of Inspire Pharmaceuticals, an ophthalmology focused company acquired by Merck & Co for US$430m in May 2011.
In collaboration with NicOx’s European headquarters, St Peter will be responsible for identifying and evaluating North American opportunities that can be exploited globally to build NicOx’s late-stage ophthalmic portfolio. He will also lead the development of NicOx’s US ophthalmology business.
NicOx announced earlier this week that it had acquired 11.8% of the shares of Altacor, a privately held ophthalmology company based in the UK, and entered into an exclusive option agreement to acquire the remaining shares.
Michele Garufi, chairman and ceo of NicOx, said: ‘Jerry has been working with NicOx as a consultant for the past five months, helping us in the ongoing evaluation of a number of ophthalmology companies and products. He will be a key asset in the creation and future expansion of our presence in the US as we work towards delivering our strategy of building an international ophthalmology company.’
St Peter joined Inspire in 2003 and held the positions of senior vice president, Ophthalmology Business Unit, svp, sales and managed markets and vp of sales.
Prior to joining Inspire, St Peter held a number of leadership positions for Muro Pharmaceutical, a private ophthalmic, pulmonary, asthma and allergy specialist pharmaceutical company.
You may also like
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing
As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Regulatory
Oncopeptides to seek EMA label expansion for Pepaxti to include third-line multiple myeloma treatment
The company has said it will submit a Type II variation to the EMA to expand Pepaxti's indication to include patients with multiple myeloma who have received at least two prior lines of therapy — a move that would double the addressable patient population and treatment cycle potential in Europe